Not all sulfa drugs are created equal

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 2166-2167

  Toler, Steven M ^a   Rodriguez, Ignacio ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AROMATIC AMINE; SULFONAMIDE; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

CLINICAL PRACTICE; CROSS REACTION; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INFECTION; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN MANIFESTATION; TOXIC EPIDERMAL NECROLYSIS;

ANALGESICS, NON-NARCOTIC; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; DIURETICS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 12844272772     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E206     Document Type: Note

References (14)

1. Petti WA. Antimicrobial agents. Sulfonamides, trimethoprim- sulfamethoxazole, quinolones, and agents of urinary tract infections. In: Hardman JE, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 2001:1171-88.
2. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-63. DOI 10.1001/jama.256.24.3358
3. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999;48:839-46. DOI 10.1046/j.1365-2125.1999. 00096.x
4. Physicians' desk reference. 57th ed. Montvale, NJ: Medical Economics, 2003.
5. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of "sulfa" allergy. Drug Saf 2001;24:239-47.
6. Depta JP, Pichler WJ. Cross-reactivity with drugs at the T cell level. Curr Opin Allergy Clin Immunol 2003;3:261-7. DOI 10.1097/00130832-200308000- 00005
7. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alpha beta T cell clones. J Clin Invest 1997;100:136-41.
8. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-35. DOI 10.1056/NEJMoa022963
9. Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003;26:187-95.
10. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999;21:2065-79. DOI 10.1016/S0149-2918(00)87238-0
11. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7. DOI 10.1056/NEJM199512143332404
12. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126:1393-407.
13. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164-73. DOI 10.1046/j.1523-1747.2000.00985.x
14. Raffensperger C, Schettler T, Myers N. Precaution: belief, regulatory system, and overreaching principle. Int J Occup Envir Health 2000;6:266-9.